Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y5S9
UPID:
RBM8A_HUMAN
Alternative names:
Binder of OVCA1-1; RNA-binding motif protein 8A; RNA-binding protein Y14; Ribonucleoprotein RBM8A
Alternative UPACC:
Q9Y5S9; B3KQI9; Q6FHD1; Q6IQ40; Q9GZX8; Q9NZI4
Background:
RNA-binding protein 8A, also known as RNA-binding motif protein 8A, RNA-binding protein Y14, and Ribonucleoprotein RBM8A, plays a crucial role in pre-mRNA splicing as part of the spliceosome. It is a core component of the exon junction complex (EJC), marking the position of exon-exon junctions in mature mRNA, thereby influencing mRNA metabolism, including export, localization, translation efficiency, and decay.
Therapeutic significance:
The involvement of RNA-binding protein 8A in Thrombocytopenia-absent radius syndrome, a disorder characterized by skeletal anomalies and thrombocytopenia, underscores its potential as a target for therapeutic intervention. Understanding the role of RNA-binding protein 8A could open doors to potential therapeutic strategies.